Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W0VR
|
|||
| Former ID |
DIB006601
|
|||
| Drug Name |
PFK-158
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Advanced cancer therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H11F3N2O
|
|||
| Canonical SMILES |
C1=CC(=CC2=C1C=CC(=N2)C=CC(=O)C3=CC=NC=C3)C(F)(F)F
|
|||
| InChI |
1S/C18H11F3N2O/c19-18(20,21)14-3-1-12-2-4-15(23-16(12)11-14)5-6-17(24)13-7-9-22-10-8-13/h1-11H/b6-5+
|
|||
| InChIKey |
IAJOMYABKVAZCN-AATRIKPKSA-N
|
|||
| CAS Number |
CAS 1462249-75-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Renal carcinoma antigen NY-REN-56 (PFKFB3) | Target Info | Inhibitor | [2] |
| BioCyc | Fructose 2,6-bisphosphate synthesis | |||
| KEGG Pathway | Fructose and mannose metabolism | |||
| HIF-1 signaling pathway | ||||
| AMPK signaling pathway | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
| Reactome | Glycolysis | |||
| WikiPathways | Metabolism of carbohydrates | |||
| AMPK Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02044861) Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib. Cancer Metab. 2014; 2(Suppl 1): P14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.